{
    "clinical_study": {
        "@rank": "75536", 
        "acronym": "Avanti", 
        "arm_group": [
            {
                "arm_group_label": "Group 1 (GnRH agonist group)", 
                "arm_group_type": "Active Comparator", 
                "description": "The long GnRH agonist protocol starts on day 21 of the preceding cycle with the administration of GnRH agonist, Decapeptyl\u00ae 0,1 mg subcutaneously daily or buserelin acetate, Suprefact\u00ae 600 \u03bcg daily intranasal. The administration of highly purified human menopausal gonadotropin (hp-HMG), Menopur\u00ae 225 IU subcutaneously is started after three weeks of desensitization. The desensitization is checked by ultrasound (absence of cysts) and hormonal measurement (Estradiol levels < 80 pg/ml, FSH \u2264 10 IU/l and progesterone < 1,5ng/ml)"
            }, 
            {
                "arm_group_label": "Group 2 (GnRH antagonist group)", 
                "arm_group_type": "Active Comparator", 
                "description": "Ovarian stimulation is started at day 2 of the menstrual cycle with 225 IU of HMG (Menopur \u00ae) subcutaneously. At day 6 of the stimulation GnRH antagonist (Orgalutran\u00ae) 0,25 mg subcutaneously is added.  Basal hormonal status will be confirmed in the antagonist group before starting."
            }
        ], 
        "brief_summary": {
            "textblock": "The aim of our study is to define the optimal ovarian stimulation protocol concerning PGD\n      and for this reason we plan a randomized controlled trial (RCT) comparing\n      gonadotropin-releasing hormone (GnRH) agonist protocol versus GnRH antagonist protocol. The\n      follicle stimulating hormone (FSH) preparation in both arms will be highly purified FSH\n      (Menopur\u00ae)."
        }, 
        "brief_title": "Preimplantation Genetic Diagnosis (PGD) With Gonadotropin-releasing Hormone (GnRH) Agonist Versus Antagonist", 
        "completion_date": {
            "#text": "June 2013", 
            "@type": "Actual"
        }, 
        "condition": [
            "Reproductive Endocrinology", 
            "Fertility", 
            "Optimal Stimulation Protocol"
        ], 
        "detailed_description": {
            "textblock": "Patients will be randomized at the outpatient clinic in two groups."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  \u2264 39 years the day of oocyte retrieval\n\n          -  BMI \u2264 29\n\n          -  cycle rank 1\n\n          -  menstrual cycle 25-36 days\n\n          -  PGD or preimplantation genetic screening (PGS) requested\n\n          -  ICSI\n\n          -  Single embryo transfer (SET) on day 5\n\n        Exclusion Criteria:\n\n          -  Polycystic Ovary Syndrome (PCOS) (according Rotterdam criteria)\n\n          -  Hormonal disturbances\n\n          -  Endometriosis grade III and IV"
            }, 
            "gender": "Female", 
            "healthy_volunteers": "No", 
            "maximum_age": "39 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "120", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "June 21, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01888744", 
            "org_study_id": "2010/010"
        }, 
        "intervention": [
            {
                "arm_group_label": "Group 1 (GnRH agonist group)", 
                "intervention_name": "GnRH agonist", 
                "intervention_type": "Drug", 
                "other_name": "Suprefact nasal spray"
            }, 
            {
                "arm_group_label": "Group 2 (GnRH antagonist group)", 
                "intervention_name": "GnRH antagonist", 
                "intervention_type": "Drug", 
                "other_name": "Orgalutran or Cetrotide"
            }, 
            {
                "arm_group_label": [
                    "Group 1 (GnRH agonist group)", 
                    "Group 2 (GnRH antagonist group)"
                ], 
                "intervention_name": "hP-hMG", 
                "intervention_type": "Drug", 
                "other_name": "Menopur"
            }, 
            {
                "arm_group_label": [
                    "Group 1 (GnRH agonist group)", 
                    "Group 2 (GnRH antagonist group)"
                ], 
                "description": "induction of final oocyte maturation", 
                "intervention_name": "Human chorionic gonadotropin", 
                "intervention_type": "Drug", 
                "other_name": "Pregnyl"
            }, 
            {
                "arm_group_label": [
                    "Group 1 (GnRH agonist group)", 
                    "Group 2 (GnRH antagonist group)"
                ], 
                "intervention_name": "Progesterone", 
                "intervention_type": "Drug", 
                "other_name": "Utrogestan vaginal tablets"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Chorionic Gonadotropin", 
                "Buserelin", 
                "Menotropins", 
                "Triptorelin", 
                "Progesterone", 
                "Ganirelix", 
                "Deslorelin"
            ]
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "Intracytoplasmic sperm injection (ICSI)", 
            "PGD", 
            "GnrH agonist", 
            "GnRH antagonist"
        ], 
        "lastchanged_date": "June 27, 2013", 
        "location": {
            "facility": {
                "address": {
                    "city": "Brussels", 
                    "country": "Belgium", 
                    "zip": "1090"
                }, 
                "name": "Centre for Reproductive Medicine"
            }
        }, 
        "location_countries": {
            "country": "Belgium"
        }, 
        "number_of_arms": "2", 
        "official_title": "The Effect of the Type of Ovarian Stimulation Protocol on PGD Results: a Prospective Randomised Trial", 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "Belgium: FAGG, Department R&D", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 4", 
        "primary_completion_date": {
            "#text": "June 2013", 
            "@type": "Actual"
        }, 
        "primary_outcome": {
            "measure": "Number of day 3 embryos for biopsy available", 
            "safety_issue": "No", 
            "time_frame": "up to 6 weeks"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01888744"
        }, 
        "responsible_party": {
            "investigator_affiliation": "Universitair Ziekenhuis Brussel", 
            "investigator_full_name": "Christophe Blockeel", 
            "investigator_title": "Professor Doctor", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "secondary_outcome": [
            {
                "measure": "Number of mature cumulus-oocyte complexes", 
                "safety_issue": "No", 
                "time_frame": "up to 6 weeks"
            }, 
            {
                "measure": "clinical pregnancy rate", 
                "safety_issue": "No", 
                "time_frame": "up to 9 months"
            }
        ], 
        "source": "Universitair Ziekenhuis Brussel", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Universitair Ziekenhuis Brussel", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "September 2010", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "June 2013"
    }
}